Cogniwell Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 31-07-2024
- Paid Up Capital ₹ 2.50 M
as on 31-07-2024
- Company Age 8 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.50 M
as on 31-07-2024
- Revenue -19.68%
(FY 2023)
- Profit 156.59%
(FY 2023)
- Ebitda 65.30%
(FY 2023)
- Net Worth 43.89%
(FY 2023)
- Total Assets -1.26%
(FY 2023)
About Cogniwell Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹2.50 M.
Naveen Nagarajan and Karthika Balachandran serve as directors at the Company.
- CIN/LLPIN
U51909KA2016PTC092566
- Company No.
092566
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Apr 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Cogniwell Pharmaceuticals Private Limited offer?
Cogniwell Pharmaceuticals Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antibacterial Drugs.
Who are the key members and board of directors at Cogniwell Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Naveen Nagarajan  | Director | 27-Apr-2016 | Current |
| Karthika Balachandran | Director | 01-Jul-2020 | Current |
Financial Performance of Cogniwell Pharmaceuticals.
Cogniwell Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 19.68% decrease. The company also saw a substantial improvement in profitability, with a 156.59% increase in profit. The company's net worth Soared by an impressive increase of 43.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cogniwell Pharmaceuticals?
In 2023, Cogniwell Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Junedreams Studios LlpActive 3 years 3 months
Naveen Nagarajan and Karthika Balachandran are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 27 Jan 2020 | ₹2.50 M | Open |
How Many Employees Work at Cogniwell Pharmaceuticals?
Cogniwell Pharmaceuticals has a workforce of 7 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cogniwell Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cogniwell Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
